A Novel Dominant Hyperekplexia Mutation Y705C Alters Trafficking and Biochemical Properties of the Presynaptic Glycine Transporter GlyT2 by Mark, Rees et al.
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Journal of Biological Chemistry
                                        
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa13960
_____________________________________________________________
 
Paper:
Gimenez, C., Perez-Siles, G., Martinez-Villarreal, J., Arribas-Gonzalez, E., Jimenez, E., Nunez, E., Juan-Sanz, J.,
Fernandez-Sanchez, E., Garcia-Tardon, N.,  et. al. (2012).  A Novel Dominant Hyperekplexia Mutation Y705C Alters
Trafficking and Biochemical Properties of the Presynaptic Glycine Transporter GlyT2. Journal of Biological Chemistry,
287(34), 28986-29002.
http://dx.doi.org/10.1074/jbc.M111.319244
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 A Novel Dominant Hyperekplexia Mutation Y705C Alters
Trafficking and Biochemical Properties of the Presynaptic
Glycine Transporter GlyT2*
Received for publication,October 31, 2011, and in revised form, June 18, 2012 Published, JBC Papers in Press, June 29, 2012, DOI 10.1074/jbc.M111.319244
Cecilio Giménez‡§¶, Gonzalo Pérez-Siles‡§, JaimeMartínez-Villarreal‡§¶, Esther Arribas-González‡¶,
Esperanza Jiménez‡§¶, Enrique Núñez‡§¶, Jaime de Juan-Sanz‡§¶, Enrique Fernández-Sánchez‡,
Noemí García-Tardón‡§¶, Ignacio Ibáñez‡, Valeria Romanelli§, Julián Nevado§, Victoria M. James**, Maya Topf‡‡,
Seo-Kyung Chung§§, Rhys H. Thomas§§, Lourdes R. Desviat‡, Carmen Aragón‡§¶, Francisco Zafra‡§¶, Mark I. Rees§§,
Pablo Lapunzina§, Robert J. Harvey**, and Beatriz López-Corcuera‡§¶1
From the ‡Departamento de BiologíaMolecular and Centro de BiologíaMolecular “Severo Ochoa,” (Consejo Superior de
Investigaciones Científicas-Universidad Autónoma deMadrid), Madrid 28049, Spain, the §Centro de Investigación Biomédica en
Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid 28029, Spain, the ¶IdiPAZ-Hospital Universitario La Paz, the
Instituto de GenéticaMédica yMolecular, IdiPAZ-Hospital Universitario La Paz, Universidad Autónoma deMadrid, Madrid 28046,
Spain, the **Department of Pharmacology, University College London School of Pharmacy, LondonWC1N 1AX, United Kingdom,
the ‡‡Institute of Structural andMolecular Biology, Crystallography, Birkbeck College, LondonWC1E 7HX, United Kingdom, and the
§§Institute of Life Science, College of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom
Background: Hyperekplexia or startle disease is caused by defects in glycinergic transmission.
Results: A new mutation pY705C in the glycine transporter GlyT2 alters protein trafficking and H and Zn2 transport
modulation.
Conclusion: Multiple pathogenic mechanisms may contribute to the complex phenotype of individuals with the Y705C
mutation.
Significance: This is the first common dominant mutation associated with hyperekplexia affecting the presynaptic glycine
transporter GlyT2.
Hyperekplexia or startle disease is characterized by an exag-
gerated startle response, evoked by tactile or auditory stimuli,
producing hypertonia and apnea episodes. Although rare, this
orphan disorder can have serious consequences, including sud-
den infant death. Dominant and recessive mutations in the
human glycine receptor (GlyR) 1 gene (GLRA1) are the major
cause of this disorder. However, recessive mutations in the pre-
synaptic Na/Cl-dependent glycine transporter GlyT2 gene
(SLC6A5) are rapidly emerging as a second major cause of
startle disease. In this study, systematic DNA sequencing of
SLC6A5 revealed a new dominant GlyT2 mutation: pY705C
(c.2114A3G) in transmembrane domain 11, in eight individu-
als from Spain and the United Kingdom. Curiously, individuals
harboring this mutation show significant variation in clinical
presentation. In addition to classical hyperekplexia symptoms,
some individuals had abnormal respiration, facial dysmor-
phism, delayed motor development, or intellectual disability.
We functionally characterized this mutation using molecular
modeling, electrophysiology, [3H]glycine transport, cell surface
expression, and cysteine labeling assays. We found that the
introduced cysteine interacts with the cysteine pair Cys-311–
Cys-320 in the second external loop of GlyT2. This interaction
impairs transporter maturation through the secretory pathway,
reduces surface expression, and inhibits transport function.
Additionally, Y705C presents altered H and Zn2 depen-
dence of glycine transport thatmay affect the function of glycin-
ergic neurotransmission in vivo.
The extracellular concentration of synaptic glycine is regu-
lated by Na/Cl-dependent glycine transporters. These pro-
teins mediate reuptake of glycine into presynaptic terminals
(GlyT2)2 and glial cells adjacent to glycinergic inhibitory neu-
rons (GlyT1) (1). Mouse knock-out studies have revealed that
glial GlyT1 is the main regulator of the extracellular glycine
concentrations (2). By contrast, neuronal GlyT2 is involved in
the removal and recycling of synaptic glycine generating a vec-
torial flow from the synaptic cleft into the terminal, supplying
substrate to the low affinity vesicular inhibitory amino acid
transporter (2, 3). Inactivation of the GlyT2 gene (Slc6a5) pre-
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vents glycine loading into synaptic vesicles, impairing inhibi-
tory glycinergic neurotransmission (4). GlyT2 knock-out mice
have a complex motor phenotype (4, 5) that mimics clinical
signs of hyperekplexia or startle disease (OMIM 149400). This
rare human disorder is characterized by an exaggerated startle
response to acoustic or tactile stimuli (6). Startle disease can
have serious consequences for neonates, including brain dam-
age and/or sudden death caused by apnea episodes. The abnor-
mal startle response, which can provoke unprotected falls
resulting in injury, can persist throughout development and
into adulthood (7). However, unlike rodent, cattle, and canine
defects (6), humans with SLC6A5mutations survive, and clini-
cal signs often resolve after the neonatal and infantile risk
period (8).
Genetic analysis of individuals with human hyperekplexia
has revealed mutations in genes for postsynaptic proteins
involved in glycinergic neurotransmission. These include the
GlyR 1 and  subunits (GLRA1 and GLRB) and proteins that
assist receptor trafficking to the synaptic membrane (9–11).
Sequencing the 16 exons of the human GlyT2 gene (SLC6A5)
also revealed that missense, nonsense, and frameshift muta-
tions affecting presynaptic glycine transport can cause hyper-
ekplexia (8, 12). The structure of a prokaryotic homologue
(LeuTAa) of the SLC6 family (13) has provided a useful model
for explaining the effects of selected missense mutations on
Na and glycine-binding residues crucial for transport activity
(6, 8, 12). It is also noteworthy that themajority of GlyT2muta-
tions were recessive, producing bi-allelic loss of function
caused by the absence of protein in the plasmamembrane or by
production of an inactive transporter (6). In the present study,
we report the identification of a novel dominant mutation
(c.2114A3G, pY705C) in exon 15 of SLC6A5. This change was
found in eight individuals from three families in two cohorts of
hyperekplexia patients that were devoid of GlyR gene muta-
tions. Functional characterization of this GlyT2 substitution
revealed the introduced cysteine impacts on transporter pro-
tein maturation through the secretory pathway and alters the
H and Zn2 dependence of glycine transport. The biochemi-
cal features of themutant transportermay produce detrimental
effects on glycinergic inhibition in vivo.
EXPERIMENTAL PROCEDURES
Molecular Genetic Analysis of the Human GlyT2 Gene
(SLC6A5)—Informed consent was obtained from all individu-
als using guidelines approved by the local ethical committees.
Patients of both sexes were studied. Patient genomic DNA was
amplified using primers for the 16 exons of the SLC6A5 gene as
previously described (8). 60 ng of genomicDNAwere amplified
using an Expand high fidelity PCR system (Roche Applied Sci-
ence) in 25-l reactions containing 10 pmol of each primer, 1
buffer with 1.5 mM MgCl2, 200 M dNTPs, and 1 unit of Taq
polymerase (Roche Applied Science). PCR conditions were
94 °C for 5 min followed by 35 cycles of 30 s at 94 °C, 30 s at
60 °C, and 30 s at 72 °C. Amplification products were analyzed
on 2% agarose gels, extracted with a QIAQuick gel extraction
kit (Qiagen), and sequenced employing BigDye Terminator
v.3.1mix (Applied Biosystems Foster City, CA). Genomic DNA
from 200 commercially available controls was obtained from
the European Collection of Cell Cultures, human random con-
trol. Population analysis was conducted by DNA sequencing of
control amplicons or using the artificially created restriction
site method (14), where an NdeI site is introduced into control
but not mutated amplicons during PCR. Electropherograms
were analyzed using Sequencher (Gene Codes Corp., Ann
Arbor, MI). Analysis of copy number variations in hyperek-
plexia genes was assessed by multiplex ligation-dependent
probe amplification. Briefly, DNA (250g) was tested using the
SALSA multiplex ligation-dependent probe amplification kit
P274 (MRC Holland), which evaluates several regions of
GLRA1, GLRB, and SLC6A5. No abnormalities (deletions nor
duplications) were observed in any of the samples evaluated,
ruling out copy number variations as a cause of hyperekplexia
in these cases.
In Silico Analysis—Conservation of themutated residueswas
assessed by alignment of orthologous and human protein
sequences using ClustalW software (15). The putatively dam-
aging effects of the predicted amino acid substitution was
assessed using the PolyPhen-2 program (16) that gives the
results as “benign,” “possibly damaging,” “probably damaging,”
or “unknown.” A GlyT2 homology model was obtained using
MODELLER (17) as previously reported (6, 18), based on the
crystal structure of LeuTAa from the bacterium Aquifex aeoli-
cus (Protein Data Bank code 2A65) (13).
Mutagenesis and Expression of Human GlyT2 cDNA in
Mammalian Cells—The human GlyT2 cDNA was cloned into
the vectors pRC-CMV (Invitrogen) and pEGFP-C1 (Clontech)
as previously described (8).Missensemutationswere generated
in pRC-CMV GlyT2 by site-directed mutagenesis using the
QuikChange kit (Stratagene). Two independent Escherichia
coli colonies carrying the mutant plasmids were characterized
by DNA sequencing and [3H]glycine transport activity. We
sequenced the full coding region of each construct to verify that
only the desired mutation had been introduced. Transient
expression in COS7 cells was performed as described (18) using
Lipofectamine Plus (Invitrogen) or NeofectinTM (MidAtlantic
Biolabs). The cells were incubated for 48 h at 37 °C, unless oth-
erwise indicated in the figure legends. For electrophysiological
recordings, the human GlyT2 cDNA was subcloned into the
vector pSP64T, generously provided by Dr. Carmen Montiel
(Universidad Autónoma of Madrid, Madrid, Spain).
Glycine Transport Assays—Transport assays in COS7 cells
were performed at 37 °C in 0.25 ml of Hepes-buffered saline
(HBS: 150 mM NaCl, 10 mM Hepes-Tris, pH 7.4, 1 mM CaCl2, 5
mM KCl, 1 mM MgSO4, 10 mM glucose). 2 Ci/ml [3H]glycine
(1.6 TBq/mmol; PerkinElmer Life Sciences) isotopically diluted
at 10 M final glycine concentration was used (19), unless a
different concentration is specified. The reactions were termi-
nated after 10min by aspiration followed by washing withHBS.
Transport was measured by subtracting the glycine accumula-
tion by mock-transfected COS7 cells from that of GlyT2 trans-
fected cells and normalizing to the protein concentration.
Kinetic analysis was performed by varying glycine concentra-
tion in the uptake medium between 10 and 1000 M.
Expression of the Human GlyT2 cDNA in Xenopus Oocytes—
Wild-type andmutant GlyT2 cDNAs were cloned in the vector
pSP64T, which contains a 1-globin promoter. Constructs
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were linearized with XbaI, and cRNAwas transcribed with SP6
polymerase and capped with 57-methylguanosine using the
mMESSAGE mMACHINE SP6 RNA kit (Ambion Inc.). Xeno-
pus laevis females were obtained from Xenopus Express
(France). The oocytes were harvested from X. laevis anesthe-
tized in tricaine methasulfonate 0.10% (w/v) solution in tap
water. All of the procedures were in accordance with the Span-
ish and European guidelines for the prevention of cruelty to
animals. The follicular membrane was removed by incubation
in a medium (90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 5 mM
Hepes, pH 7.4) containing 300 units/ml collagenase (Type 1;
Sigma) for 1 h. Wild-type or mutant mRNAs (50 ng) were
injected into defolliculated stage V and VI X. laevis oocytes.
The oocytes were maintained in Barth’s medium (88 mMNaCl,
1mMKCl, 0.33mMCa(NO3)2, 0.41mMCaCl2, 0.82mMMgSO4,
2.4 mM NaHCO3, and 10 mM Hepes, pH 7.4), and transport
or electrophysiological experiments were assayed 5 days
post-injection.
Two-microelectrode Voltage-Clamp Recordings from Xeno-
pus Oocytes—Electrophysiological recordings were obtained
after incubation of the injected oocytes at 18 °C in standard
oocyte solution (100 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 10 mM Hepes, pH adjusted to pH 7.5 with HCl). Two-
electrode voltage clamp was used to measure and control the
membrane potential and to monitor the capacitative currents
using Axoclamp 900A (Axon Instruments), digitized using a
Digidata 1440 (Axon Instruments). Both instrumentswere con-
trolled by pCLAMP software (Axon Instruments), and the
results were analyzed using Clampfit 10.2 software (Axon
Instruments). Recordings were performed at room tempera-
ture using standard micropipettes filled with 3 M KCl (resist-
ance varied between 0.5 and 2 M). The oocytes were held at
40 mV, and to obtain current-voltage (I-V) relations, the
pulse protocol consisted of 350-ms voltage steps between130
and 50 mV in 20 mV steps. The currents were subjected to
low pass filtering at 100 Hz.
Cell Surface Labeling—Thiol-specific biotinylation and total
surface biotinylation was performed with MTSEA-biotin
(Toronto Research Chemicals Inc., Toronto, Canada) and
sulfo-NHS-SS-biotin (Pierce) on transfected COS7 cells as
described (20, 21). 0.5 mM MTSEA-biotin or 1.5 mg/ml sulfo-
NHS-SS-biotin and a 3-h incubation with streptavidin-agarose
beads (Sigma) were used. Biotinylated proteins (B) were eluted
from the beads with Laemmli buffer (40 mM Tris, pH 6.8, 2%
SDS, 10% glycerol, 0.1 M DTT, 0.01% bromphenol blue) for 10
min at 70 °C and then analyzed in Western blots (7.5% SDS-
PAGE) with anti-GlyT2 antibody (Santa Cruz). Protein bands
were visualized by ECL and quantified on a GS-710 calibrated
imaging densitometer from Bio-Rad with Quantity One soft-
ware, using film exposures in the linear range. Loading controls
were performed by reprobing Western blot membranes using
an anti-calnexin antibody. Standard errors were calculated
from at least three separate experiments.
GlyT2 Subcellular Localization—Wild-type or mutant
GlyT2 in pEGFP-C1 were transfected in MDCK cells and 48 h
later were subjected to immunofluorescence as described pre-
viously (22) using the antibody against the indicated marker
protein. Secondary antibodies were coupled to Alexa Fluor
555. Alternatively, the cells were transfected with pEGFP-C1
GlyT2 (23) and were fixed with 4% paraformaldehyde in PBS.
The cells were visualized by confocal microscopy on a LSM510
confocal microscope (Zeiss) using a vertical microscope Axio
Imager.Z1 M (Zeiss).
RESULTS
Patient Information—A total of 16 probands from Spain and
188 from the UK with clinical diagnosis of hyperekplexia, all of
which had proved gene-negative in screens of GLRA1 and
GLRB, were provided from neurological units. Genomic DNA
samples from the patients were screened for SLC6A5 muta-
tions. Clinical features of patients carrying the novel mutation
in the SLC6A5 gene are summarized below. Fig. 1 shows the
pedigrees of the patient families.
A
II-2
Typical clinical findings (stiffness, startle, etc) 
Tenseness , hypertonia , intolerance to noise
Nocturnal ”kicks”, exaggerated hypermobility  
B
II-2
C
 V-1  V-4
IV-6
III-2
IV-5
Family 1
Family 2
Family 3
I-2
FIGURE 1. Pedigree of families 1 (A), 2 (B), and 3 (C). Individuals are num-
bered according to their position in the pedigree lines as I, II, III, and IV, and
then each individual from left to right as 1, 2, 3, etc. Males and females are
represented by squares and circles, respectively. Shaded symbols represent
individuals with the Y705C mutation or who are/were affected, with clinical
signs observed.
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The first patient from family 1, V-1, displayed perinatal onset
persistent crying and hypertonia. This was ameliorated when
she was removed from the neonatal intensive care unit and was
placed in a quiet, low stimuli environment. Physical examina-
tion at day 7 revealed an exaggerated startle reaction and prom-
inent head retraction. She had delayedmotor development and
showed a severe degree of intellectual disability. With the sec-
ond patient from family 1, V-4, concern was raised when the
child was 1 month old because of hypertonia and abnormal
crying. Neurological evaluation demonstrated abnormal head
retraction and hypertonia, which improved during sleep.
Patient IV-5 from family 1 had similar neonatal behavior toV-1;
he “kicked” and had exaggeratedmovements during rest at bed,
mainly when sleeping. Patient IV-6 in family 1 showed some
intolerance to noise and crowded places, andwhen hewas a boy
suffered from attacks of stiffness precipitated by surprise or
school tests.
Patient II-2 in family 2 was a girl who presentedwith stiffness
and frequent falling and was intellectually intact. Patient II-2 in
family 3 had perinatal hypertonia with clonus (variable, par-
tially resolving in sleep) and triggered startle episodes (parox-
ysmal clonic movements). In addition she had abnormal respi-
ration with prominent apnea episodes. Physically she had
several dysmorphic features: tongue protrusion, striking excess
neck skin folds, large atrial-septal defect, short palpebral fis-
sures, small carp-like mouth, subtly low set ears, single palmar
crease, contractures at the knees, and overlapping clenched fin-
gers and hands. Cranial calcification was also seen. Her MRI
demonstrated small focal areas of signal change in the deep,
subcortical whitematter of both cerebral hemispheres and pos-
sible gyral swelling. She died aged 21 weeks having spent the
majority of her life in pediatric intensive care. The mother is
apparently asymptomatic. She was physically examined at the
age of thirty-one and no abnormality or excessive startle was
detected.
Genetic Analysis—Genomic DNA samples from 204 individ-
uals with hyperekplexia who had tested negative for disease-
causing mutations inGLRA1 (5q33.1) andGLRB (4q32.1) were
scanned on all 16 coding exons and extended flanking intronic
regions of SLC6A5 (11p15.1), encoding human GlyT2. Several
single-nucleotide polymorphisms present in patients and con-
trols were found. In addition,DNA sequence analysis revealed a
heterozygous nonsynonymous change (c.2114A3G) in exon
15 in four of the patients analyzed (patients V-1 and V-2 of
family 1, patient II-2 of family 2, and patient II-2 of family 3).
Familial analysis revealed the presence of this sequence variant
in four more individuals (Fig. 1). This change was not detected
in 600 unrelated, normal control chromosomes (data from the
United Kingdom; not detected in 400 normal control chromo-
somes, Caucasian samples), as assessed using two different
techniques (see “Experimental Procedures”). This mutation
resulted in a tyrosine (TAT) to cysteine (TGT) substitution at
position 705 (pY705C) in transmembrane domain 11 (TM11;
Fig. 2).Homologymodeling ofGlyT2using the crystal structure
of the LeuTAa (13) located Tyr-705 at the carboxyl-terminal
portion of the TM11, near the extracellular face of the trans-
porter (Fig. 2B). A loss of a hydrogen bondwith the side chain of
Glu-701 is predicted. Phylogenetic comparisons of the TM11
region of GlyT2 show high evolutionary conservation of Tyr-
705 (Fig. 2C). Alignment of GlyT2 with other Na/Cl-depen-
dent neurotransmitter transporters of the SLC6 family demon-
strates that a tyrosine is found at the equivalent position inmost
human neurotransmitter transporters from the GABA, amino
acid, and monoamine subfamilies (norepinephrine transporter
and dopamine transporter) with the exception of GABA trans-
porter 1 and serotonin transporter (Fig. 2D). This suggests that
Tyr-705 has a relevant role for transporter function within this
superfamily and accordingly, the Y705C substitution was pre-
dicted to be “probably damaging” in PolyPhen-2 analysis, with a
score of 1.000.
Mutagenesis and Functional Characterization—Functional
consequences of the Y705C mutation were initially assessed
by assaying [3H]glycine uptake of recombinant wild-type and
mutant GlyT2 after transient expression in COS7 cells (Fig.
3A). The Vmax of glycine transport by the Y705C mutant was
reduced to 60% as compared with wild-type GlyT2 (23 
2.5 for the Y705C versus 38  3.2 nmol of Gly/mg of pro-
tein/5 min for wild type). The co-expression of wild-type and
Y705C transporters resulted in a Vmax of 30  3.1 nmol of
Gly/mg of protein/5 min, representing 79% of wild-type
GlyT2. This value is close to the predicted average value of
the activity of each transporter population. A slight but sig-
nificant increase of the Km for glycine was observed in the
Y705C mutant when expressed alone. Investigation of other
features of glycine transport by GlyT2 indicated that sensi-
tivity to Na and Cl, the ions required for transport, was
unaffected in Y705C mutant, and the sensitivity of the
mutant transporter to the inhibition by the selective GlyT2
inhibitor ALX1393 was unchanged as compared with wild-
type GlyT2 (data not shown).
Additional functional characterization was performed by
overexpressing wild-type and mutant GlyT2 in Xenopus
oocytes to examine the electrophysiological properties of both
proteins. As shown in Fig. 3B, glycine-induced inward currents
were observed in oocytes expressing either wild-type GlyT2 or
the Y705C mutant. In agreement with the reduced Vmax for
glycine transport observed in COS cells, maximal currents
recorded from oocytes were 35% lower than observed for
wild-typeGlyT2.We also studied the voltage dependence of the
observed currents by employing a voltage-clamp protocol con-
sisting of long square pulses from 130 to 50 mV. The cur-
rent triggered by glycine showed inward rectification for both
transporters (Fig. 3C). The I-V relationships were similar in
shape, suggesting no alteration of the voltage dependence of
glycine transport. However, at each voltage examined, the cur-
rent mediated by wild-type GlyT2 was larger than that of the
Y705C mutant.
Plasma Membrane Expression—One possible explanation
for the reduction in Vmax for glycine transport of the Y705C
mutant could be impaired plasma membrane expression. We
determined the levels of transporters present in the plasma
membrane using two different approaches. First, we expressed
EGFP-tagged wild-type GlyT2 or the Y705C mutant in MDCK
cells (Fig. 4A), immunolabeling the cells for the plasma mem-
brane marker protein E-cadherin (22, 24). The percentage of
Y705C co-localization with the plasma membrane marker was
GlyT2 Y705CMutation Associated with Hyperekplexia
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76.8 2.3% compared with wild-type GlyT2. In addition, sur-
face labeling with the nonpermeant reagent Sulfo-NHS-SS-bi-
otin of the proteins expressed in the plasmamembrane ofCOS7
cells allowed the isolation and quantification of the surface-
resident transporters. In agreement with this finding, the
Y705C mutant amounted for 68.9  5.7% of wild-type GlyT2
levels (Fig. 4B). GlyT2 protein expressed in cultured cells
appears as a mature 100-kDa protein band, which is the form
present on the plasma membrane, and a 75-kDa underglycosy-
lated immature transporter (25). As shown in Fig. 4B, the
Y705C mutant showed a higher proportion of immature pre-
cursor compared with wild-type GlyT2, so that the mature/
immature protein ratio was 50% reduced for themutant. This is
highly suggestive of a deficiency in the biogenesis and process-
ing of the Y705C mutant along the secretory pathway, slowing
the transformation of the immature precursor into the mature
protein. However, we did not observe clear co-localization of
the transportermutantwith the endoplasmic reticulummarker
(calnexin), nor with other cellular markers such as TGN38,
Rab5, or the early endosome marker EEA1 as compared with
wild-type GlyT2 (Fig. 4C). This suggests that the mutant pro-
tein is not arrested in a precise compartment of the secretory
pathway but perhaps progresses slowly along the endomem-
brane system. In addition, no alteration of the typical GlyT2
A
C
wtGlyT2   T  A  T  Tyr 
Y705C   T  G  T  Cys 
D
B
Homo sapiens VCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIP
Mus musculus VCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIP
Rattus norvegicus VCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIP
Canis familiaris VCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIP
Monodelphis domestica VCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIP
Gallus gallus VCWAFVTPTILTFILCFSFYQWEPMTYGAYHYPGWSMVLGWLMLACSVIWIP
Danio rerio VCWAFVTPTILTFILALSLYQWKVMTYEDYTYPNWSMVLGWLMVICSVIWIP
Strongylocentrotus p. VNWSAFTPGLMVFVLFFNWLQWVEPSYNG-PFPTWAVIIGWLMTTMSLIWIP
hGlyT2 SLC6A5 CWAFVTPTILTFILCFSFYQWEPMTYGS-YRYPNWSMVLGWLMLACSVIWIP
hGlyT1 SLC6A9 CWRFVSPAIIFFILVFTVIQYQPITYNH-YQYPGWAVAIGFLMALSSVLCIP
hPROT  SLC6A7 CWLFLSPATLLALMVYSIVKYQPSEYGS-YRFPPWAELLGILMGLLSCLMIP
hTAUT  SLC6A6 SWAVITPVLCVGCFIFSLVKYVPLTYNKTYVYPNWAIGLGWSLALSSMLCVP
hGAT1  SLC6A1 CWSFFTPIIVAGVFIFSAVQMTPLTMGN-YVFPKWGQGVGWLMALSSMVLIP
hGAT2  SLC6A13 CWLFLTPAVCTATFLFSLIKYTPLTYNKKYTYPWWGDALGWLLALSSMVCIP
hGAT3  SLC6A11 CWMIMTPGICAGIFIFFLIKYKPLKYNNIYTYPAWGYGIGWLMALSSMLCIP
 hBGT1  SLC6A12SWLFLTPGLCLATFLFSLSKYTPLKYNNVYVYPPWGYSIGWFLALSSMVCVP
hCRTR  SLC6A8 CWSFFTPLVCMGIFIFNVVYYEPLVYNNTYVYPWWGEAMGWAFALSSMLCVP
hNET   SLC6A2 CWKFVSPAFLLFVVVVSIINFKPLTYDD-YIFPPWANWVGWGIALSSMVLVP
hDAT   SLC6A3 CWKLVSPCFLLFVVVVSIVTFRPPHYGA-YIFPDWANALGWVIATSSMAMVP
hSERT  SLC6A4 CWVAISPLFLLFIICSFLMSPPQLRLFQ-YNYPYWSIILGYCIGTSSFICIP
FIGURE 2. Genetic and structural analysis of the Y705C mutant. A, partial sequences of exon 15 from control and patient 1 DNAs, respectively. Note the
heterozygous single-nucleotide polymorphism c.2114A3G changes the codon TAT to TGT, resulting in a pY705C substitution in GlyT2. B, molecularmodel of
GlyT2 showing the localization of Tyr-705 in TM11. C, phylogenetic comparison of TM11 regions of GlyT2 containing the amino acid Tyr-705 (in red).
D, sequence alignment of GlyT2 TM11 region in human SLC6 familymembers. Sequenceswere obtained fromNCBI (www.ncbi.nlm.nih.gov) andwere aligned
using ClustalW software and MUSCLE alignment server.
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apical sorting (26) was observed in polarizedMDCKcells grow-
ing in Transwells (Fig. 4D), because the asymmetric distribu-
tion of the Y705Cmutant was coincident with that of wild-type
GlyT2.
Substitution Analysis of Tyr-705—Multiple amino acid sub-
stitutions at Tyr-705 showed a comparable, although smaller
impairment of plasma membrane localization than that
observed for Y705C (Fig. 5A). This suggests that the defect in
transporter biogenesis is not only due to the introduction of
Cys-705 but also due to Tyr-705 removal. Moreover, different
Tyr-705 substitutions had heterogeneous effects on glycine
transport (Fig. 5B). Y705F or Y705A had no or low impact,
showing 100  12 and 80  10% of wild-type transport,
respectively. By contrast, Y705K and Y705S surpassed wild-
type activity by 108  11 and 135  10%, respectively.
Remarkably, substitution by glutamic acid (Y705E) pro-
foundly impaired function resulting in 37  4% of wild-type
transport. Because transport activity of these mutants does
not correlate with membrane expression, Tyr-705 substitu-
tions affect the activity of surface transporters in addition to
membrane trafficking.
To further investigate the effect of the cysteine substitution
found in the hyperekplexia patients and taking into account
that this residue can potentially formdisulfide bondswith other
cysteines, we performed DTT treatment on cells expressing
Tyr-705 mutants. Interestingly, DTT rescued the transport
activity of the Y705C mutant from 61  6 to 100  7% of
wild-type transport (Fig. 5B). As expected, this effect was spe-
cific for the Y705C mutant, suggesting that glycine transport
activity was restored by reduction of a disulfide bond involving
Cys-705. DTT can readily cross the plasmamembrane andmay
affect both transporter trafficking and transport activity. To
distinguish between these two possibilities, we used the non-
permeant reducing agentsMesNa (27) and TCEP (28) (Fig. 5,C
and D). Both reagents consistently produced lower recovery of
Y705C function than DTT. This suggests the internal access of
the reagent is important for the activation. The small activation
produced by the negatively charged MesNa might be due to
its decreased reactivity compared with the uncharged TCEP.
However, none of the nonpermeant reagents reached the
activation produced by DTT. We therefore assumed that
DTT can improve a defect in the processing/folding of the
transporter during biogenesis, whereas MesNa or TCEP can
only “activate” plasma membrane-localized Y705C. Consis-
tent with this theory, Fig. 5D shows that MesNa and TCEP
promoted higher activation of the Y705C mutant than wild-
type GlyT2 or the Y705A mutant.
DTT Increases Plasma Membrane Expression of the Y705C
Mutant—Next, we wished to know whether DTT activation
targets the intracellular Y705C transporter and increases
FIGURE 3.Glycine transport and electrophysiological characterization ofwild-typeGlyT2 and the Y705Cmutant.A, COS7 cells expressing the indicated
transporterswere assayed for 3[H]glycine transport during 10min inHBS containing 150mMNaCl in thepresenceof increasingglycine concentrations from0.5
to 1mM. Experimental datawere fitted to hyperbolae. Kinetic parameters are indicated on the graph. *, significantly different fromwild-type GlyT2, p 0.05 in
Student’s t test. B, inward currents evoked by glycine in representative oocytes expressing wild-type GlyT2 or the Y705C mutant. The cells were voltage-
clamped at 40 mV, and 1 mM glycine was superfused for the period indicated by the solid bar. Histogram represents arithmetic means  S.E. (n 	 5–10
oocytes) of normalized inward currents for wild-type GlyT2 and the Y705C mutant. *, significantly different from wild-type GlyT2, p 0.05 in Student’s t test.
C, current-voltage plots of the glycine-mediated inward currents of wild-type GlyT2 and Y705Cmutant determined by subtracting, in each case, the currents
observed in the absence of glycine.
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plasma membrane levels sufficiently to restore the wild-type
levels of surface-active GlyT2. For this purpose, we treated
COS7 cells expressing wild-type GlyT2 or the Y705C mutant
with DTT for increasing periods of time up to 30min andmea-
sured [3H]glycine transport and surface biotinylation in parallel
(Fig. 6, A and B). As shown above, glycine transport by the
Y705C mutant was rapidly increased by DTT, reaching wild-
type levels of activity in 3–4 min and continuing up to 10 min
before reaching a plateau (Fig. 6A). A 10-min period has been
shown to be sufficient for trafficking to the Golgi of polytopic
proteins expressed inmammalian cells (29).We havemeasured
comparable time courses of plasma membrane expression for
GlyT2.3 In fact, extended time periods in DTT increased the
amount of surface mutant transporter with a slightly delayed
time course. This indicates a fast activation of surface-inserted
transporter (5min) followed by a slower increase in the amount
of plasma membrane protein (10–30 min; Fig. 6B, left histo-
gram). A decrease in the levels of the immature proteinwas also
observed (Fig. 6B, right histogram). By contrast, the quantity of
wild-type GlyT2 present in the plasma membrane was slightly
diminished by DTT, and the transport activity was only slightly
3 E. Arribas-González, P. Alonso-Torres, C. Aragón, and B. López-Corcuera,
manuscript in preparation.
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FIGURE4.Cell andplasmamembraneexpressionofwild-typeGlyT2andY705C.A, immunofluorescencequantificationof plasmamembrane transporters.
Wild-type EGFP-tagged GlyT2 or Y705C expressed in MDCK cells for 48 h were immunolabeled for the plasma membrane marker E-cadherin (E-cad). Two
channel confocal images were obtained (green for GlyT2 and red for E-cadherin), and regions occupied by E-cadherin were taken as plasma membrane and
regions inside the cadherin staining were taken as intracellular, using the Image J ROI manager. After applying an automatic threshold to adjust images, the
fluorescence intensity was measured separately for membrane and intracellular regions, and the percentage of transporter in plasma membrane was calcu-
lated (histogram). This process was performed at least in 150 cells/condition. *, p 0.05 values calculated using Student’s t test by comparingwild-type GlyT2
with the Y705C mutant. B, COS7 cells expressing wild-type GlyT2 or Y705C mutant were subjected to biotinylation as described under “Experimental Proce-
dures.” 8g of total (lanes T) and nonbiotinylated proteins (lanes NB) and 24g of biotinylated proteins (lanes B) were subjected toWestern blotting for GlyT2
detection, and the membranes were reprobed for calnexin immunoreactivity as a loading control. Lower panel, densitometric analysis. Black bars, total
transporter that was biotin-labeled (B as a % of T) as percentage of that of wild-type GlyT2.Open bars, mature/immature transporter ratio (100 kDa/75 kDa) as
a percentage of the ratio (100 kDa/75 kDa) for wild-type GlyT2. *, p 0.05 in Student’s t test. C, MDCK cells expressing wild-type EGFP-tagged GlyT2 or Y705C
were immunolabeled for calnexin (CNX, endoplasmic reticulum marker) or early endosome antigen 1 (EEA1, early endosome marker). No significantly differ-
ence in co-localizationwas observed.D, MDCK cells transfectedwithwild-type EGFP-taggedGlyT2 or Y705Cwere plated on cell culture filter inserts andgrown
to confluence. Samples were examined by laser scanning confocal microscopy. Left panel, en face views. Right panel, x-z cross-sections. The x-z cross-sections
are derived from the indicated transept lines.
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increased. To confirm that DTT can induce Y705C exocytosis,
we treated MDCK cells expressing EGFP-tagged transporters
with DTT and monitored co-localization with the plasma
membrane marker E-cadherin (Fig. 6, C and D). As shown in
Fig. 4A, the percentage of Y705C co-localization with the
plasmamembranemarker was65% compared with wild-type
GlyT2, and the co-localization was increased by 40% by DTT
(Fig. 6D).
Y705C Forms anAberrant Disulfide Bond Interfering with the
Cys-311–Cys-320 Pair—One possible explanation of the recov-
ery of Y705C function with DTT could be that Cys-705 forms a
disulfide bond with one of the 23 endogenous cysteines present
in GlyT2 (Fig. 7B). Such a covalent bond could impair glycine
transport and/or transporter trafficking. Cleavage of this bond
by DTT could restoremutantmembrane expression and trans-
port activity. To test this possibility, we took advantage of the
predicted external accessibility of Cys-705 and labeled the cells
expressing the transporters with the nonpermeable SH-specific
reagent MTSEA-biotin (Fig. 7, A, E, and F). This probe reacts
with externally accessible free thiol groups in an aqueous envi-
ronment. In control conditions, the fraction of SH-labeled
Y705C mutant was higher than that of wild-type GlyT2 (2
0.5-fold; Fig. 7, A and E). Taking into account that the mem-
brane expression of Y705C is65% of wild-type GlyT2 (Fig. 4),
this means the cysteine specific label is 3-fold higher in the
Y705C mutant than in wild-type GlyT2. In fact, pretreatment
with DTT, which increases mutant membrane expression to
wild-type levels (Fig. 6), yielded 3-fold higher labeling for
Y705C compared with wild-type GlyT2 (Fig. 7, A, E, and F).
This suggests that the Y705C mutation involves structural
effects that increase cysteine availability. When the cells were
pretreated with N-ethylmaleimide in the absence of DTT to
prevent SH reagent reaction with the free cysteines, both trans-
porters showed reduced labeling (Fig. 7A). Under this condi-
tion, the Y705C labeling was65% of that of wild-type GlyT2,
reflecting lower membrane expression. Moreover, if N-ethyl-
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FIGURE5.SubstitutionanalysisofTyr-705andeffectofDTTonglycine transport.Transiently transfectedCOS7cells expressingwild-typeGlyT2ormutants
with the indicated amino acids at position 705, were subjected to biotinylation as described in Fig. 4 to determine plasmamembrane expression (A) or treated
with vehicle or 12mMDTT (B) or 2.5mMDTT (D) or the specified concentrations of the indicated reducing agents (C) and then assayed for [3H]glycine transport.
In B, * indicates significantly different fromwild-type GlyT2, p 0.05 in Student’s t test. In C andD, ** indicates p 0.01, and * indicates p 0.05 by analysis of
variance. Lanes T, total proteins; lanes NB, nonbiotinylated proteins; lanes B, biotinylated proteins.
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maleimide pretreatment was performed, and then DTT was
added to release cysteines from disulfides, the DTT-induced
increase in SH-specific label of the Y705C mutant was higher
than that of wild-type GlyT2 (Fig. 7A). This result suggests the
presence of an additional disulfide bond in the Y705C mutant.
To identify the binding partner for Cys-705, we inspected the
three-dimensional structure of GlyT2 and selected several cys-
teine residues based on location that might permit the for-
mation of an intra- or intermolecular disulfide bond with Cys-
705 (Fig. 7B). Selected cysteineswere individually substituted to
serine to form Cys 3 Ser mutants. Single substitutions were
introduced into the Cys-705 background to generate double
mutants (CXS/Y705C), whichwere tested forDTTactivation of
glycine transport (Fig. 7,C andD). Two of themutants (C311S/
Y705C and C320S/Y705C) were activated to a smaller extent
than the other mutants (Fig. 7D). This result supports a poten-
tial interaction between a cysteine at position 705 and cysteines
at positions 311 and 320. Accordingly, C311S/Y705CorC320S/
Y705C doublemutants display a significantly reducedMTSEA-
biotin labeling compared with the Y705C mutant, indicating
that Cys-705 can interact with either Cys-311 or Cys-320 (Fig.
7, E and F). Cysteines 311 and 320 are located in the second
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Procedures” (B). A, transport data are expressed as percentages of wild-type GlyT2 transport activity, which was 2.8 0.3 nmol of Gly/mg of protein/10min. *,
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FIGURE 7.MTSEA-biotin labeling and transport activity of Y705C and GlyT2 cysteine mutants. A, COS7 cells expressing wild-type GlyT2 or Y705C were
treated with vehicle or 50 mM N-ethylmaleimide (NEM) for 10 min, washed, and treated with HBS or 12 mM DTT in HBS for 30 min, washed, and subjected to
MTSEA-biotinylation as described under “Experimental Procedures.” Upper panel, Western blot for GlyT2 detection of a SDS-PAGE loaded with 10 g of total
(lanes T) and 100 g of biotinylated proteins (lanes B). Lower panel, densitometric analysis of the percentage of total transporter (B as a % of T) that was
MTSEA-biotin-labeled in each condition as percentage of control wild-typeGlyT2. ***, Significantly different fromwild-typeGlyT2, p 0.001 in Student’s t test.
B, upper panel, molecular model of GlyT2 showing the localization of Tyr-705 and some of the endogenous cysteines (black). Lower panel, location of the
Cys-311–Cys-320 pair in the second external loop as compared with Cys-705 on schematic GlyT2 secondary structure. C and D, effect of DTT on glycine
transport by cysteine to serinemutants in the background of wild-type GlyT2 or the Y705Cmutant. COS7 cells expressing wild-type GlyT2, Y705C, cysteine to
serine mutants (CXS), or Y705C/cysteine to serine double mutants (CXS/Y705C) for 48 h were assayed for [3H]glycine transport for 10 min after being treated
with vehicle (C) or with 12 mM DTT at 22 °C for 5 min (D). E, COS7 cells expressing the indicated transporters were treated with vehicle (DTT) or DTT (DTT)
for 30 min, washed, and MTSEA-biotin-labeled; streptavidin-agarose bound proteins were run in nonreducing (DTT) or reducing (DTT) SDS-PAGE and
subjected toWestern blotting as above. F, densitometric analysis of the percentage of total transporter that was MTSEA-biotin-labeled in each condition. For
clarity, this was expressed as percentage of the respective wild-type GlyT2 in each condition. Significantly different from the Y705C singlemutant: *, p 0.05;
**, p 0.01 in Student’s t test.
GlyT2 Y705CMutation Associated with Hyperekplexia
AUGUST 17, 2012•VOLUME 287•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 28995
 at CARDIFF UNIVERSITY, on Septem
ber 18, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
external loop (EL2) of GlyT2 (Fig. 7B). This region cannot cur-
rently be accurately modeled because of significant divergence
in sequence and length compared with LeuTAa (18, 21). How-
ever, equivalent conserved cysteines have been shown to form a
disulfide bond in other members of the SLC6 family (30, 31).
Unexpectedly, although C311S and C320S mutants should
both have a single unpaired extracellular cysteine like Y705C,
they have much lower cysteine labeling in the absence of DTT.
In addition, they display very high MTSEA-biotin label after
DTT treatment (Fig. 7, E and F). This unexpected result made
us consider the possibility that the unpaired cysteine from the
Cys-311–Cys-320 disulfide might form a disulfide bond with
another monomer, creating disulfide-linked dimers. Fig. 8A
shows that C311S and C320Smutants form disulfide-mediated
dimers on the cell surface (band indicated by an asterisk), which
are cleaved to monomers in the double C311S/Y705C or
C320S/Y705C mutants. This reinforces the evidence that Cys-
705 interacts with Cys-311 and Cys-320 (Fig. 8B).
A further relevant question is whether the trafficking defect of
Y705C affects the expression of wild-type GlyT2. To answer this,
we co-expressedwild-type andmutantGlyT2differentially tagged
with EGFP (Fig. 8C). The Y705C mutant reduces total wild-type
GlyT2 expression by 10–20% when expressed at 1:1 ratio. This is
comparablewith the effect of a nonrelevant protein, the glutamate
transporterGLT1 (Fig. 8D).At ahigherGlyT2-Y705Cratio (1:3), a
slight reduction of GlyT2 expression by the Y705C mutant was
observed, although this effect was not due to a reduced delivery to
the plasma membrane (Fig. 8E). Moreover, wild-type GlyT2 co-
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expressed with Y705C reduces the expression of the mutant by
10–20% (data not shown). These results indicate that the traffic
defect of the Y705C mutant is not dominant when it is co-ex-
pressed at the same dose as wild-type GlyT2.
HDependence of Glycine Transport Is Inverted in the Y705C
Mutant—According to the above data, DTT is likely to disrupt
an aberrant disulfide bond in theY705Cmutant. This facilitates
exocytosis and induces the emergence of the mutant trans-
porter on the cell surface. In addition, the Y705C substitution
predicts the introduction of a local negative charge on the sur-
face of the transporter because of the more acidic nature of the
cysteine side chain (pKa of 8.3 versus 10.3 for tyrosine). Because
the protonation state of protein ionizable groups is dependent
on pH, we tested the pH dependence of Tyr-705 mutants con-
taining titratable side chains (Fig. 9). In agreement with pub-
lished data on GABA transporters (32, 33), wild-type GlyT2 is
FIGURE 9. Effect of pH on glycine transport by wild-type GlyT2 and the Tyr-705mutant. Transiently transfected COS7 cells expressing wild-type GlyT2 or
mutants with the indicated amino acid substitutions at position 705 were assayed for [3H]glycine transport for 5 min in HBS containing 150 (A and C) or 75 (B
and C) mM NaCl at 10 M or the indicated final glycine concentration and pH. Control GlyT2 transport values at pH 7.4 were 1.4 0.2 and 0.73 0.1 nmol of
Gly/mg of protein/5 min at 150 and 75 mM NaCl, respectively. Mean pH change was significantly different from wild-type GlyT2. *, p  0.05 by analysis of
variance with Dunnett’s post hoc test. C, kinetics of glycine transport at low pH. COS7 cells expressing wild-type GlyT2, the Y705C mutant, or the indicated
combination of the respective cDNAs were assayed for [3H]glycine transport at pH 7.4 or 5.4 for 5 min in HBS containing 150 or 75 mM NaCl and glycine
concentrations increasing from 0.5 M to 1 mM. Experimental data were fitted to hyperbolae. The kinetic parameters are indicated on the graphs. Mean pH
change significantly different from wild-type GlyT2. *, p 0.05 in Student’s t test.
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inhibited at low pH, showing 50–60% transport activity at
pH 5.4. The inhibition was even higher when assayed in low
external sodium (Fig. 9, A and B). This is in agreement with the
proposed competition of the two cations in the external trans-
porter vestibule (32, 33). When the assay was performed at the
physiological NaCl concentration (150 mM), the wild-type
response to low pH was also observed for the Y705C, Y705E,
and Y705A mutants (Fig. 9A). However, lowering the external
pH in the presence of low NaCl concentrations (75 mM) pro-
duced a differential response in the Y705C and Y705Emutants.
They became activated at pH5.4 instead of inhibited, indicating
an altered proton dependence of transport in these Tyr-705
substitutions (Fig. 9B). Furthermore, the pH dependence of
wild-type GlyT2 co-transfected at a 1:1 cDNA ratio with the
Y705C mutant resembled that of the mutant rather than wild-
type GlyT2. This suggests a dominant phenotype for Y705C
(Fig. 9, A and B). Therefore, we characterized the transport
kinetics at acidic pH (Fig. 9C). The Y705C mutant had
increased Vmax at pH 5.4 when expressed alone and in co-ex-
pression with wild-type, especially at low sodium. This is in
contrast to wild-type GlyT2 that showed a 50% reduction in
Vmax value at acidic versus neutral pH. In addition, a general
increase in Km at low pH was observed for all the transporters.
This was more pronounced for Y705C and the co-expression,
especially at low sodium (2-, 5-, and 2.5-fold for wild-type
GlyT2, Y705C, and Y705Cwild-type GlyT2, respectively).
Taken together, these data indicate that the Y705Cmutation in
GlyT2 induces an altered response to proton modulation of
glycine transport.
Y705C Mutant Is Partially Resistant to Zn2 Inhibition of
Glycine Transport—Protons and metal transition dications are
competitive inhibitors of several crucial mediators of glyciner-
gic neurotransmission, such as the glycine receptor (34–36)
and the glycine transporter GlyT1 (37, 38). Because H and
Zn2 frequently bind to overlapping intersubunit sites (39–
41), and the binding of transition dications can induce cysteine
deprotonation (42), we tested the effect of Y705C substitution
on the sensitivity of GlyT2 to Zn2. AlthoughGlyT2 is not very
sensitive to this cation (38), we observed a low but significant
inhibition ofGlyT2 transport byZn2 (Fig. 10). As expected,we
found that Zn2 sensitivity of wild-type transport was pH-de-
pendent, being higher at pH 7.4 than 5.4, in agreement with the
competitive nature of H and Zn2 inhibition (35, 38, 39). By
contrast, the inhibition byZn2of theY705Cmutantwasmuch
less sensitive to the presence of protons and slightly more pro-
nounced at acidic pH. As expected from the proton response
shown above, the co-expression of wild-type GlyT2 and the
Y705C mutant also resulted in Y705C behavior, confirming a
dominant phenotype (Fig. 10A). Fig. 10B shows that the IC50 for
Zn2 inhibition of wild-type GlyT2 was significantly increased
at acidic pH from63 10 at pH7.4 to 466 42Mat pH5.4. By
contrast, the Y705C mutant had IC50 values of 100  15 and
189 19 M at these same pH values. The co-expressed wild-
type GlyT2 and Y705Cmutant displayed IC50 values of 99 10
and 198  22 M, which are close to those of Y705C mutants.
Further kinetic analysis of glycine transport in the presence of
Zn2 showed a significantly lower decrease in the Vmax of
transport by the Y705C-containing transporters than for wild-
type GlyT2. In addition, a higher increase in Km was observed.
These data confirm the reduced sensitivity of Y705C-contain-
ing glycine transporters to Zn2 inhibition (Fig. 10C).
DISCUSSION
We have identified a novel missense mutation in SLC6A5,
encoding GlyT2, present in eight individuals from three fami-
lies in two cohorts of hyperekplexia patients fromSpain and the
United Kingdom. Themutation results in a tyrosine to cysteine
substitution at residue 705 (Y705C) in transmembrane domain
11 (TM11). This change was found in the heterozygous state in
all positive cases suggesting a dominant mode of inheritance.
This contrasts with themajority of the previously characterized
GlyT2 mutations that were inherited in a recessive or com-
poundheterozygous state (11). Y705C-harboring patients show
significant variability in clinical presentation. As well as classi-
cal hyperekplexia symptoms, certain individuals exhibited
abnormal respiration, facial dysmorphism, delayed motor
development, or intellectual disability. This may be due to a
complex phenotype caused by the mutation or to the presence
of additional unknown mutations or modifiers. However, no
other potential disease-causing mutations were detected in
SLC6A5. Study of the biochemical properties of the mutant
transporter in cultured cells revealed that the introduced cys-
teine affects several aspects of transporter biochemistry. These
include impaired transporter protein maturation through the
secretory pathway and an alteration of H and Zn2 depend-
ence of glycine transport. The latter feature constitutes a dom-
inant effect, because it is observed when the mutant is
expressed alone and alsowhenmutant andwild-type transport-
ers are co-expressed.
The Y705C substitution introduces a free thiol in the place of
a hydroxyl-containing side chain. Thiol labeling with imper-
meant cysteineMTS reagents confirmed that Cys-705 is acces-
sible from the exterior of the plasmamembrane, as predicted by
molecular modeling. Therefore, the Y705Cmutant exposes the
introduced cysteine to the lumen of the secretory pathway cis-
ternae during trafficking. This seems to be detrimental for
transporter biogenesis, because Y705C has reduced expression
at the plasma membrane, together with a higher proportion of
immature precursor compared with wild-type GlyT2. This is in
agreement with recent reports indicating that polymorphisms
containing an uneven number of cysteine residues in extracel-
lular loops impair the expression of G-protein-coupled recep-
tors and other plasma membrane proteins. This feature has
frequently been associated with disease states (29, 43–45). Res-
toration of Y705C membrane expression to wild-type levels
with the permeable thiol reagent DTT and experiments using
SH-specific and surface labeling of cells expressing the trans-
porters suggest that Cys-705 is involved in aberrant disulfide
bond formation. Cys-705 binding partners are either of twoEL2
cysteines that are likely to form a disulfide bond in wild-type
GlyT2 (C311-C320 pair) (30, 31). This interference is probably
conformation-dependent, because EL2 may approach TM11
during the inward-facing conformation (46). Disruption of this
aberrant bond with reducing agents may facilitate plasma
membrane arrival and/or the conformational movements
needed for transport in the surface-resident transporter. How-
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ever, it is not clear whether Y705C expression is lower because
a proper disulfide bridge cannot be formed or because the aber-
rant disulfide bond distorts the protein structure, because both
conditions are present in Y705C. The single C311S and C320S
mutants show approximately half the membrane expression of
wild-type GlyT2, suggesting that the lack of the endogenous
disulfide bond is detrimental for surface expression. However,
the unusual behavior of these mutants prevents us from draw-
ing clear conclusions. The fact that Y705C andwild-typeGlyT2
are differentially sensitive to low concentrations of reducing
agents but are inhibited by higher concentrations (Fig. 5C and
data not shown) suggests that the aberrant disulfide bond
involving Cys-705 is more sensitive to cleavage than the Cys-
311–Cys-320 disulfide bond. The recovery of the expression in
the Y705C mutant might be due to the cleavage of aberrant
disulfide bondswithout affecting theCys-311–Cys-320 pairing.
It is also possible that GlyT2 requires disulfide-mediated
dimerization for plasmamembrane expression as has been sug-
gested for other SLC6 transporters (31) and that this process is
disrupted by the Y705Cmutation. BecauseGlyT2multimeriza-
tion has been proposed to be required for plasma membrane
localization (47), this is an issue that will require further study.
The Y705C substitution is also predicted to introduce a local
negative charge at the transporter surface. The endogenous
Tyr-705 residue with a typical pKa value of 10.3 would be
mostly protonated at physiological pH. By contrast, the side
chain of Cys-705 would, in theory, be also protonated, but the
more acidic pKa value (close to 8.3) makes the probability of
ionization higher than for the tyrosine side chain. In addition, a
high dielectric medium favors cysteine deprotonation, whereas
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FIGURE 10. Effect of Zn2 on glycine transport by wild-type GlyT2 and the Y705Cmutant. Transiently transfected COS7 cells expressing wild-type GlyT2,
the Y705Cmutant, or the indicated combinations of the respective cDNAswere assayed for [3H]glycine transport for 5min inHBS containing 75mMNaCl at the
indicatedpHand10M final glycine concentration (AandB) or increasingglycine concentrations (C) in thepresenceof the indicatedZnCl concentrations (A–C).
NaCl was isotonically substituted by choline chloride. B, dose-response data were fit to logistic curves. C, transport data were fitted to hyperbolae, and kinetic
parameters were obtained from the best fit. Mean change significantly different from wild-type GlyT2. *, p 0.05 in Student’s t test.
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a low dielectric medium favors the protonated state (42).
BecauseCys-705 is extracellular, it is therefore likely tobe inahigh
dielectric environment. Deprotonation is also favored by the pres-
ence of transition metal dications, which may perform a metal-
assisted deprotonation of cysteine side chains, especially if bound
to polarizable ligands (42). Other factors such as the possible
hydrogen-bonding network including the cysteine may affect the
pKa (48).All of these factorsmaydriveCys-705 tobedeprotonated
at physiological pH. By contrast, acidic pHmay displace the equi-
librium toward the protonated form. GlyT2 transport activity
seems to be sensitive to the protonation state of Cys-705, and pro-
tonationmayactivate themutant transporter.Therefore, although
glycine transport by wild-type GlyT2 is inhibited at low pH, the
Y705Cmutant is resistant to this inhibition.
Functional analysis of the Y705C mutant has revealed the
existence of an unexpected fine-tuning mechanism of glycine
transport by external H, with Tyr-705 playing a central role.
Interestingly, the GlyR is also inhibited by protons and the pro-
ton-binding site also involves a hydroxyl-containing residue
(Thr-112), which when substituted by a tyrosine (but not by a
neutral amino acid) preserves the H sensitivity of the receptor
(49). Both Tyr-705 in GlyT2 and Thr-112 in GlyRs are highly
conserved. A threonine is found at the equivalent position in all
pH-sensitive GlyR, GABAA, and GABAC receptors. Equally, a
Tyr-705 equivalent is found in many SLC6 family members,
suggesting that this tyrosine might have a general role in pH
sensitivity of Na-and Cl-dependent neurotransmitter trans-
porters. The location of Tyr-705 in an extracellular accessible
region of the transporter would fulfill one of the prerequisites
for H-binding sites, which are usually located outside the
membrane electric field (49, 50). Proton and transition dication
binding sites are usually overlapping in pH- and Zn2-sensitive
proteins (34–36, 38). In the GlyR, Thr-112 also forms part of
the group of crucial residues involved in regulation by Zn2
(35). In several plasmamembrane proteins present in inhibitory
synapses, H/Zn2-binding sites are contributed by several
adjacent subunits (35, 49, 51, 52). This structural requirement
might also hold true for GlyT2 andwould sustain the dominant
nature of the aberrant pH sensitivity and Zn2 dependence of
the Y705C mutant co-expressed with wild-type GlyT2.
In summary, we have identified a novelmissensemutation in
GlyT2 associatedwith hyperekplexia and described altered bio-
chemical properties of the mutant transporter. The Y705C
mutation affects several aspects of transporter biochemistry
including impaired transporter proteinmaturation through the
secretory pathway and an alteration of H and Zn2 depen-
dence of glycine transport. Any of these features may contrib-
ute to the etiology of the disease. In addition to effects in patho-
physiological conditions such as inflammation and ischemia,
transient changes in extracellular pH occur under physiological
conditions. For example, in synaptic transmission, the acidic
contents of transmitter vesicles cause an extracellular acid shift
within the synaptic cleft (53, 54) and may reduce the local Na
concentration. Different sources of protons have been sug-
gested in the synapse: acidic contents after vesicle fusion, incor-
poration of the vesicular ATPase to the plasma membrane, or
extrasynaptic sources such as H ion exchangers and voltage-
gated H conductances (51). These pH changes are especially
relevant during repetitive electrical stimulation that may pro-
duce acid shifts of30 s in duration (53). Acidification reduces
the duration of glycinergic synaptic currents and accelerates
desensitization of the receptor significantly affecting the kinet-
ics of glycinergic neurotransmission (54). Increased external
pH potentiated, whereas decrease inhibited both the amplitude
and frequency of glycinergic miniature inhibitory postsynaptic
potential currents, suggesting the involvement of both presyn-
aptic and postsynaptic mechanisms (54). In addition, Zn2 is
highly enriched in synaptic vesicles, fromwhich it can be co-re-
leased with glutamate in an activity-dependent manner (36).
Zn2modulates both current responsesmediated by excitatory
and inhibitory neurotransmitter receptors and the efficacy of
transporter-driven neurotransmitter reuptake (55). We
hypothesize that Y705C mutant may alter the kinetics of gly-
cinergic inhibition by taking up glycine when the transporter is
supposed to be inhibited by synaptic H or Zn2. This may
disrupt the coordination of neurotransmitter release and sub-
sequent reuptake, leading to a damaging effect, mainly during
repetitive firing. In addition, the mutant transport activity,
which is resistant to two “natural” synaptic inhibitors, may pre-
vent or dampen the interaction of glycine with GlyRs by simple
competition. Finally, defective trafficking of the mutant may
reduce the uptake of glycine at neutral pH, thus reducing the
availability of transmitter in the terminal for synaptic vesicle
loading. Future work performed in neuronal preparations will
reveal towhat extent glycinergic neurotransmission is impaired
by the Y705C mutation.
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